Go or no go? Agile and Lipocine hope to make it third time lucky
Smaller projects dominate the list, but this doesn’t make them any less important for November’s hopefuls.
Upcoming events – Crucial data for Neurocrine and Redhill
Neurocrine Biosciences is hoping to untick the box on its previous Tourette’s failures, while Redhill hopes that it has the Talicia keys.
Redhill snatches defeat from the jaws of victory in Crohn's
Redhill Biopharma has claimed success with its novel Crohn's disease therapy, but there is more to this "victory" than meets the eye.
Upcoming events – Crowded markets ahead for TG and Redhill
TG and Redhill are expecting phase III data soon, but both have a fight ahead to make their mark even if their projects succeed.
